Subcutaneous Herceptin Receives FDA Approval for HER2-Positive Breast Cancer Treatment

On 28 February, the United States Food and Drug Administration (FDA), for HER2-positive early-stage breast cancer in certain patients, together with chemotherapy, approved the subcutaneous (under-the-skin) form of trastuzumab, trastuzumab / hyluronidase-oysk (Herceptin Hylecta) , a smart drug. Eligible patients were defined as node-positive, or node-negative and hormone-negative, or having one high-risk factor. The FDA also approved it for HER2-positive metastatic breast cancer in patients previously receiving one or more lines of chemotherapy for metastatic disease, with paclitaxel or alone as trastuzumab / hyluronidase-oysk.
This new drug contains the same monoclonal antibody as conventional trastuzumab, but is formulated with recombinant human hyaluronidase PH20 to permit subcutaneous administration. Conventional trastuzumab (Herceptin) is given by intravenous (into a vein) infusion over 30-90 minutes, while trastuzumab / hyaluronidase-osk comes as ready-to-use syringes administered subcutaneously in 2-5 minutes.
Studies Leading to FDA Approval of Subcutaneous Trastuzumab: HannaH, SafeHER, and PrefHER
FDA approval for early-stage HER2-positive breast cancer was obtained from the results of 3 clinical trials:
- In the phase III HannaH study, chemotherapy plus neoadjuvant and adjuvant trastuzumab / hyaluronidase oysk was compared with intravenous trastuzumab. Subcutaneous trastuzumab and hyaluronidase-oysk achieved blood levels equivalent to intravenous trastuzumab, with similar clinical efficacy results. The pathological complete response rate was % 45.4 with trastuzumab / hyaluronidase oysk and % 40.7 with trastuzumab alone.
- The phase III SafeHER study of adjuvant trastuzumab / hyaluronidase-oysk was consistent with the known safety profiles and tolerability data for intravenous trastuzumab and trastuzumab / hyaluronidase-oysk.
- PrefHER tested patients’ administration preferences and found that most (% 86) preferred trastuzumab / hyaluronidase oysk to intravenous trastuzumab.
In people receiving trastuzumab / hyaluronidase oysk for early breast cancer, the most common adverse effects were fatigue, joint pain, diarrhea, injection-site reaction, upper respiratory tract infection, rash, muscle pain, nausea, headache, swelling, flushing, fever, cough, and extremity pain.
Sources
fda.gov - 28 February 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.